Did Global Innovative Platforms Inc. (GIPL) report any related-party transactions for the new directors?

The company states there have been no transactions since the beginning of its last fiscal year, and no proposed transactions, involving the new directors or their immediate family members that would require disclosure under Item 404(a) of Regulation S-K, indicating no reportable related-party dealings.

Board expansion at Global Innovative Platforms (GIPL) adds four directors

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Global Innovative Platforms Inc. expanded its board of directors from one to four members, effective April 1, 2026, and appointed Elyssa Jacob Campbell, James C. Jones, Anthony (Tony) Porter, and David Mauer as directors.

The new directors bring experience in animal health research, legal practice, healthcare operations, business development, and partnership management, aligning with the company’s focus on innovative breath-based diagnostics for animal health. The company states there are no family relationships, appointment-related arrangements, or related-party transactions requiring disclosure, and that any committee assignments or director compensation will be detailed in a later filing.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Board size: 1 to 4 directors Effective date of appointments: April 1, 2026 Number of new directors: 4 directors

3 metrics

Board size 1 to 4 directors Authorized increase effective April 1, 2026

Effective date of appointments April 1, 2026 New directors begin service

Number of new directors 4 directors Campbell, Jones, Porter, Mauer appointed to board

Key Terms

Emerging growth company, Item 5.02, Item 404(a) of Regulation S-K, written consent, +1 more

5 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Item 5.02 regulatory

"Item 5.02 Departure of Directors or Certain Officers; Election of Directors"

Item 404(a) of Regulation S-K regulatory

"material interest that would require disclosure under Item 404(a) of Regulation S-K"

Delaware General Corporation Law regulatory

"acting pursuant to Delaware General Corporation Law, does hereby consent"

A set of state laws that acts like a rulebook for how corporations are formed, governed, and dissolved in Delaware. It lays out legal duties for company leaders, protections and voting rights for shareholders, and rules for mergers and other big transactions, giving investors clearer expectations about how corporate decisions are made and disputes are resolved—similar to having standardized traffic laws for business behavior.

Understanding 8-K Material Events →

05/20/2026 - 05:13 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2026

Global Innovative Platforms Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-56235	85-3816149
(State of other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

570 Lexington Green Lane, Sanford, Florida 32771

(Address of principal executive office)

321-230-3739

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
		None

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 1, 2026, the Board of Directors (the “Board”) of Global Innovative Platforms Inc. (the “Company”) appointed the following individuals to serve as directors of the Company, effective immediately:

·Elyssa Jacob Campbell Ms. Campbell has served as Chief Executive Officer of Animal Diagnostics and Research Solutions, Inc. since May 2025. She has also served as an Assistant Research Scientist at the University of Georgia since December 2025 and previously as Laboratory Manager at the University of Georgia from March 2019 to November 2025. Her background includes extensive experience in animal health research, laboratory management, and diagnostic development, which aligns with the Company’s focus on innovative breath-based diagnostics for animal health.

·James C. Jones Mr. Jones has served as an Attorney at the Law Offices of James C. Jones since January 2021. His professional experience includes legal practice, which may provide governance and compliance perspectives to the Board.

·Anthony (Tony) Porter Mr. Porter has served as Managing Director of Bluestar360, LLC since March 2023 and as Board Advisor to World Wealth Act since May 2025. Previously, he held senior roles at Universal Health Services, including Senior Divisional Director from December 2013 to March 2023 and Director of Business Development from January 2008 to December 2013, as well as Corporate Director at Methodist LeBonheur Healthcare from February 2006 to December 2007. His experience spans healthcare operations, business development, and advisory roles.

·David Mauer Mr. Mauer has served as President of University Place Partners since 2010 and as Board Member and Vice President of 40-50 Tenants Corporation since 2005. His background includes leadership in partnership management and board service.

There are no family relationships among any of the newly appointed directors and any other directors or executive officers of the Company. There are no arrangements or understandings between any of the newly appointed directors and any other person pursuant to which such director was appointed. There have been no transactions since the beginning of the Company’s last fiscal year, nor are there any proposed transactions, in which the Company was or is to be a participant and in which any of the newly appointed directors (or any immediate family member) had or will have a direct or indirect material interest that would require disclosure under Item 404(a) of Regulation S-K.

The Company will provide information regarding any committee appointments or compensation arrangements for these directors in a subsequent filing if and when determined.

EXHIBITS

Exhibit 99.1 - Written Consent of The Sole Director of Global Innovative Platforms Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

May 20, 2026	Global Innovative Platforms Inc.

	/s/ Andrew Brown
	Name: Andrew Brown
	Title: Chief Executive Officer and Chief Financial Officer

WRITTEN CONSENT

OF THE SOLE DIRECTOR OF

GLOBAL INNOVATIVE PLATFORMS INC.

The undersigned, being the sole director of Global Innovative Platforms Inc., a Delaware corporation (the “Company”), acting pursuant to Delaware General Corporation Law, does hereby consent to the adoption of, and does hereby adopt, the following resolutions as of April 1, 2025 with the same force and effect as if they had been adopted at a duly convened meeting of the Board of Directors of the Company:

WHEREAS, the Board of Directors of the Company currently consists of one (1) member; and

WHEREAS, the Board of Directors has determined that it is in the best interests of the Company and its shareholders to increase the size of the Board of Directors to four (4) members to provide additional expertise and oversight as the Company advances its business objectives in innovative platforms and related technologies; and

WHEREAS, the Board of Directors has identified qualified individuals to serve as additional directors;

NOW, THEREFORE, BE IT RESOLVED, that effective April 1, 2026, the number of authorized directors of the Company is increased from one (1) to four (4); and it is further

RESOLVED, that the following individuals are hereby appointed to serve as directors of the Company, effective April 1, 2026, to hold office until their successors are duly elected and qualified or until their earlier resignation or removal:

·Elyssa Jacob Campbell

·James C. Jones

·Anthony (Tony) Porter

·David Mauer; and it is further

RESOLVED, that the officers of the Company are hereby authorized and directed to take all actions necessary or advisable to effectuate the foregoing resolutions, including but not limited to the preparation and filing of any required disclosures with the Securities and Exchange Commission (including an amendment to or new Form 8-K reporting the board increase and director appointments under Item 5.02), updating corporate records, and issuing any necessary notices; and it is further

RESOLVED, that all actions previously taken by the officers or agents of the Company that are consistent with the foregoing resolutions are hereby ratified, confirmed, and approved.

RESOLVED, that this consent may be executed by facsimile signature or docusign and upon such execution shall have the same force and effect as an original.

IN WITNESS WHEREOF, the undersigned, being the sole director of the Company, consents hereto in writing as of the date first written above and directs that this instrument be filed with the minutes of proceedings of the Board of Directors of the Company.

______________________________

Andrew Brown

Source: View Original Filing on SEC EDGAR

FAQ

What board changes did Global Innovative Platforms Inc. (GIPL) disclose?

Global Innovative Platforms Inc. increased its board size from one to four directors, effective April 1, 2026, and appointed Elyssa Jacob Campbell, James C. Jones, Anthony (Tony) Porter, and David Mauer to serve as directors until their successors are elected or they resign or are removed.

Who are the new directors of Global Innovative Platforms Inc. (GIPL)?

The company appointed Elyssa Jacob Campbell, James C. Jones, Anthony (Tony) Porter, and David Mauer. Their backgrounds span animal health research, legal practice, healthcare operations, business development, advisory roles, and partnership management, which the company indicates align with its innovative diagnostic platforms and related technologies focus.

Are there family or appointment arrangements involving Global Innovative Platforms Inc. (GIPL) new directors?

The company reports no family relationships between the newly appointed directors and any existing directors or executive officers, and no arrangements or understandings with any person pursuant to which these individuals were appointed, suggesting standard board nominations without special appointment agreements.

Will Global Innovative Platforms Inc. (GIPL) disclose committee assignments or compensation for the new directors?

Global Innovative Platforms Inc. indicates it will provide information on any committee appointments or compensation arrangements for the new directors in a subsequent filing if and when those matters are determined, so those governance and pay details are not yet specified here.

What corporate action authorized Global Innovative Platforms Inc. (GIPL) board expansion?

A written consent of the sole director, Andrew Brown, acting under Delaware General Corporation Law, approved increasing the number of authorized directors from one to four effective April 1, 2026, and authorized officers to make required SEC disclosures and update corporate records to reflect the changes.

Filing Exhibits & Attachments

5 documents

Press Releases

EX-99.1 CONSENT OF DIRECTOR 5.8 KB